MAIA Biotechnology reports 2022 net loss of $15.7M; cash $10.9M; Phase 2 NSCLC trial underway in Europe

MAIA Biotechnology, Inc.

Net loss $15.7M for 2022 vs $12.6M in 2021; R&D expenses $8.9M (up from $3.5M) due to THIO trial startup.
Cash $10.9M at Dec 31, 2022 vs $10.6M at Dec 31, 2021; G&A expenses $6.1M (up from $4.3M) including $1.1M ratchet share expense.
First two patients dosed in Phase 2 THIO-101 trial in Europe for advanced NSCLC; plan to initiate second Phase 2 trial THIO-102.
Pre-IND meeting with FDA for U.S. expansion; positive feedback on manufacturing and clinical development plan.
Preclinical data presented at SITC for THIO in hepatocellular carcinoma; new telomere-targeting molecule program advanced.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAIA Biotechnology, Inc. reported for the year ended December 31, 2022 results: net income approximately $15.7 million.

Period: for the year ended December 31, 2022
Net income: approximately $15.7 million
Result: reported results

Exact text from the filing

Net loss was approximately $15.7 million for the year ended December 31, 2022, as compared to net loss of approximately $12.6 million for the year ended December 31, 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-004328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.